BRPI0918833A2 - macrociclos peptidomiméticos - Google Patents

macrociclos peptidomiméticos

Info

Publication number
BRPI0918833A2
BRPI0918833A2 BRPI0918833A BRPI0918833A BRPI0918833A2 BR PI0918833 A2 BRPI0918833 A2 BR PI0918833A2 BR PI0918833 A BRPI0918833 A BR PI0918833A BR PI0918833 A BRPI0918833 A BR PI0918833A BR PI0918833 A2 BRPI0918833 A2 BR PI0918833A2
Authority
BR
Brazil
Prior art keywords
peptidomimetic macrocycles
macrocycles
peptidomimetic
Prior art date
Application number
BRPI0918833A
Other languages
English (en)
Inventor
Huw M Nash
Jia-Wen Han
Justin Noehre
Rosana Kapeller-Libermann
Tomi K Sawyer
Original Assignee
Aileron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc
Publication of BRPI0918833A2 publication Critical patent/BRPI0918833A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0918833A 2008-09-22 2009-09-22 macrociclos peptidomiméticos BRPI0918833A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9917208P 2008-09-22 2008-09-22
PCT/US2009/057927 WO2010034028A1 (en) 2008-09-22 2009-09-22 Peptidomimetic marcrocycles

Publications (1)

Publication Number Publication Date
BRPI0918833A2 true BRPI0918833A2 (pt) 2015-12-08

Family

ID=41581947

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918833A BRPI0918833A2 (pt) 2008-09-22 2009-09-22 macrociclos peptidomiméticos

Country Status (8)

Country Link
US (1) US20120115783A1 (pt)
EP (1) EP2342214A1 (pt)
JP (1) JP2012503024A (pt)
CN (1) CN102197046A (pt)
AU (1) AU2009294871A1 (pt)
BR (1) BRPI0918833A2 (pt)
CA (1) CA2737916A1 (pt)
WO (1) WO2010034028A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
WO2010033879A2 (en) * 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
CN102482336B (zh) 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2627662B1 (en) 2010-10-13 2015-09-16 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US9605026B2 (en) 2013-01-19 2017-03-28 New York University Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
WO2014138429A2 (en) * 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
EP4023295A1 (en) * 2020-12-29 2022-07-06 IDP Discovery Pharma, S.L. Vegf-regulating peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8143228B2 (en) * 2004-07-12 2012-03-27 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment
US8940864B2 (en) * 2006-10-05 2015-01-27 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
CA2678941C (en) * 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems

Also Published As

Publication number Publication date
CA2737916A1 (en) 2010-03-25
CN102197046A (zh) 2011-09-21
US20120115783A1 (en) 2012-05-10
JP2012503024A (ja) 2012-02-02
AU2009294871A1 (en) 2010-03-25
EP2342214A1 (en) 2011-07-13
WO2010034028A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
FIC20250029I1 (fi) neratinibi
BRPI0918948A2 (pt) macrociclos peptidomiméticos
EP2376100A4 (en) PEPTIDOMIMETIC MACROCYCLES
EP2488193A4 (en) IMPROVED PEPTIDOMIMETIC MACROCYCLES
BRPI0907754A2 (pt) Macrociclos peptidomiméticos terapêuticos
BRPI0920889A2 (pt) macrociclos peptidomiméticos.
BRPI0920899A2 (pt) macrociclos peptidomiméticos com propriedades melhoradas
EP2603600A4 (en) PEPTIDOMIMETIC MACROCYCLES
FIC20230025I1 (fi) neratinibi
EP2310407A4 (en) BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0907376A2 (pt) Fotobiorretador
BRPI0914649A2 (pt) Piprazolo-quinazolinas
EP2329802A4 (en) EMBEDDED AUDIOPHONE
FI20086158A0 (fi) Imidatsopyridiinijohdannaiset
EP2337157A4 (en) CONNECTOR
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909634A2 (pt) 2-aminoquinolinas
BRPI0922728A2 (pt) combinação de herbicida-antídoto
DE112009001946A5 (de) Mobelauszugsführung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
AT507449A3 (de) Dämmstoffbefestiger
AT506244A3 (de) Verbindungskörper

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.